Distinct osteoblastic differentiation potential of murine fetal liver and bone marrow stroma-derived mesenchymal stem cells

✍ Scribed by Olivia Fromigué; Zahia Hamidouche; Sébastien Chateauvieux; Pierre Charbord; Pierre J. Marie

• Publisher: John Wiley and Sons
• Year: 2008
• Tongue: English
• Weight: 232 KB
• Volume: 104
• Category: Article
• ISSN: 0730-2312
• DOI: 10.1002/jcb.21648

✦ Synopsis

Abstract

Bone marrow‐derived mesenchymal stem cells (MSC) are able to differentiate into osteoblasts under appropriate induction. Although MSC‐derived osteoblasts are part of the hematopoietic niche, the nature of the stromal component in fetal liver remains elusive. Here, we determined the in vitro osteoblastic differentiation potential of murine clonal fetal liver‐derived cells (AFT024, BFC012, 2012) in comparison with bone marrow‐derived cell lines (BMC9, BMC10). Bone morphogenetic protein‐2 (BMP2) increased alkaline phosphatase (ALP) activity, an early osteoblastic marker, in AFT024 and 2012 cells, whereas dexamethasone had little or no effect. BMP2, but not dexamethasone, increased ALP activity in BMC9 cells, and both inducers increased ALP activity in BMC10 cells. BMP2 increased ALP mRNA in AFT024, 2012 and BMC9 cells. By contrast, ALP was not detected in BMC10 and BFC012 cells. BMP2 and dexamethasone increased osteopontin and osteocalcin mRNA expression in 2012 cells. Furthermore, bone marrow‐derived cells showed extensive matrix mineralization, whereas fetal liver‐derived cell lines showed no or very limited matrix mineralization capacity. These results indicate that the osteoblast differentiation potential differs in bone marrow and fetal liver‐derived cell lines, which may be due to a distinct developmental program or different microenvironment in the two hematopoietic sites. J. Cell. Biochem. 104: 620–628, 2008. © 2007 Wiley‐Liss, Inc.